The purpose of this trial is to evaluate the efficacy and safety of NPC-12G gel (topical
formulation of sirolimus) versus placebo gel to facial angiofibroma and other skin lesions in
patients with tuberous sclerosis complex (TSC)
Drug: NPC-12G gel
Drug: Placebo gel
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT02635789
Ages eligible for Study
3 Years and older
Genders eligible for Study
Accepts Healthy Volunteers
Male or female patients 3 years old or greater at the time of informed consent
Patients who are diagnosed as definite diagnosis according to diagnostic criteria for tuberous sclerosis complex (International Tuberous Sclerosis Complex Consensus Conference 2012)
Patients with three or more papules of angiofibroma ( >= 2 mm in diameter with redness in each) on the face at screening tests
Patients who are not suitable for therapy with laser or surgery, or who do not want therapy with laser or surgery
Patients or his/her guardian who give a written informed consent in understanding and willingness after having received enough explanation of the test drug and the current trial plan
Patients who are hard to apply the test drug topically with keeping compliance
Patients with clinical findings such as erosion, ulcer and eruption on or around the lesion of angiofibroma, which may affect assessment of safety or efficacy
Patients who are hard to be taken pictures of their lesions adequately in such cases that they may not follow instruction of stillness
Patients with a history of hypersensitivity to alcohol or allergy to sirolimus
Patients who have complications such as malignant tumor, infection, serious heart disease, hepatic function disorder, renal function disorder or blood disorders which severity are considered by investigator as grade 2 or more severe with reference to
''Concerning classification criteria for seriousness of adverse drug reactions of medical agents''
Patients who have complications such as diseases unsuitable for the trial participation, for examples, uncontrolled diabetes (fasting blood glucose level >140 mg/dL or postprandial blood glucose level > 200 mg/dL), dyslipidemia (cholesterol level > 300 mg/dL or > 7.75 mmol/L, triglycerides level > 300 mg/dL or > 3.42 mmol/L), etc.
Patients who have taken drugs with mTOR inhibitory action including sirolimus, everolimus or temsirolimus within 12 months before the initial registration
Patients who have applied topical tacrolimus on the lesion of angiofibroma within 3 months before the initial registration
Patients who have received therapy with laser or surgery to the lesion of angiofibroma within 6 months before the initial registration
Female patients who may be pregnancy or are lactating
Patients who cannot agree to take appropriate measures of contraception until completion of post-treatment phase or follow-up period after discontinuation from informed consent
Patients who have participated in other clinical trial and have taken a trial drug within 6 months before the initial registration
Others, patients who are considered by the investigator as unsuitable for participation in the trial
All locations for NCT02635789
Graduate School of Medicine, Osaka University
Suita, Osaka, Japan, 565-0871
View full eligibility
Tris trial is registered with FDA with number: NCT02635789. The sponsor of the trial is Nobelpharma and it is looking for 62 volunteers for the current phase.
Official trial title: A Double-blind, Randomized, Placebo-controlled Phase III Trial to Investigate the Efficacy and Safety of NPC-12G Gel (Topical Formulation of Sirolimus) to Angiofibroma and Other Skin Lesions in Patients With Tuberous Sclerosis Complex
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.